Stem cell startup proclaims ‘inflection point’ for medicine as mass production nears

Stem cell startup proclaims ‘inflection point’ for medicine as mass production nears

It’s harvest day at the Karolinska Institute in Stockholm. As sunshine bathes the leafy university campus, scientists inside the labs work under cool fluorescent light. Clad in green protective gear, they tend meticulously to test tubes within hermetically sealed cleanrooms. The containers hold the fruits of today’s labour: mesenchymal stem cells (MSCs). Each cell is barely a quarter the width of a human hair but wields remarkable power. MSCs re…